Primary Parotid Non-Hodgkin's Lymphoma: A Case Report.
- Author:
Geon CHO
1
;
In Suck SUH
;
Kyoung Seok TAK
;
Young Kyu PARK
;
Eung Yeol KO
;
Ha Min SUNG
;
Mi Kyung SHIN
Author Information
1. Department of Plastic and Reconstructive Surgery, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea. sismdps@chol.com
- Publication Type:Case Report
- Keywords:
Non Hodgkin's lymphoma;
Parotid gland
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
Doxorubicin;
Follow-Up Studies;
Humans;
Lymphoma;
Lymphoma, Non-Hodgkin;
Male;
Middle Aged;
Parotid Gland;
Recurrence;
Salivary Glands;
Vincristine
- From:Journal of the Korean Cleft Palate-Craniofacial Association
2010;11(2):99-102
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Primary malignant lymphomas of the salivary glands are uncommon, representing only 1.7% to 3.1% of all salivary neoplasms and 0.6% to 5% of all tumors and tumor-like lesions of the parotid gland. Lymphomas of the parotid glands are usually manifestations of a systemic disease process but primary lymphomas of the parotid glands are rare. Most of these lesions are classified as extranodal non-Hodgkin's lymphoma. We report the clinicopathological features of primary malignant lymphoma of the parotid gland based on an analysis of our cases. METHODS: The subject was a 48-year-old male patient with a malignant lymphoma originating in the parotid gland, which had been slowly increasing in size over previous 6 months. The diagnosis was established by MRI and a superficial lobectomy. After diagnosis, the patient was referred to an oncologist for staging and medical treatment. RESULTS: The stage was IIIA. The patient was treated with chemotherapy following surgery with rituximab and CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisolone). The tumor was controlled successfully by chemotherapy. The patient was followed up for 1 year with no relapse. CONCLUSION: A case of primary non-Hodgkin's lymphoma of the parotid gland was treated with a superficial parotidectomy and chemotherapy. The disease was well controlled after a 1 year follow-up.
